Drug Type Small molecule drug |
Synonyms OX-MPI, BI-1029539, GS 248 + [1] |
Target |
Mechanism PGES inhibitors(Prostaglandin E synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Start Date29 Dec 2020 |
Sponsor / Collaborator Gesynta Pharma ABStartup [+1] |
Start Date02 Nov 2020 |
Sponsor / Collaborator Gesynta Pharma ABStartup |
Start Date08 Sep 2020 |
Sponsor / Collaborator Gesynta Pharma ABStartup |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Microvascular Disease | Phase 2 | US | 30 Jan 2022 | |
Microvascular Disease | Phase 2 | US | Gesynta Pharma ABStartup | 30 Jan 2022 |
Raynaud Disease | Phase 2 | BE | Gesynta Pharma ABStartup | 29 Dec 2020 |
Raynaud Disease | Phase 2 | NL | Gesynta Pharma ABStartup | 29 Dec 2020 |
Raynaud Disease | Phase 2 | PL | Gesynta Pharma ABStartup | 29 Dec 2020 |
Raynaud Disease | Phase 2 | GB | Gesynta Pharma ABStartup | 29 Dec 2020 |
Retinitis Pigmentosa | Phase 2 | BE | Gesynta Pharma ABStartup | 29 Dec 2020 |
Retinitis Pigmentosa | Phase 2 | NL | Gesynta Pharma ABStartup | 29 Dec 2020 |
Retinitis Pigmentosa | Phase 2 | PL | Gesynta Pharma ABStartup | 29 Dec 2020 |
Retinitis Pigmentosa | Phase 2 | GB | Gesynta Pharma ABStartup | 29 Dec 2020 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | - | 14 | (Part I GS-248 Formulation A) | fopemncbyu(anpxciksku) = nwfpghttgq ruxiomimsm (mjdegyjrwe, ahrytgsbks - soksbgavui) View more | - | 31 Aug 2021 | |
(Part I GS-248 Formulation B) | fopemncbyu(anpxciksku) = zmccxilxop ruxiomimsm (mjdegyjrwe, zuwahmuzex - zumxvbaplm) View more |